Search

Your search keyword '"Haenel, Mathias"' showing total 6 results
Start Over Author "Haenel, Mathias" Journal blood advances
6 results on '"Haenel, Mathias"'

1. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

Author

Heidenreich, Falk, Falk, Bose, Baldauf, Henning, Massalski, Carolin, Schäfer, Gesine, Rücker-Braun, Elke, Altmann, Heidi, Sauter, Jürgen, Solloch, Ute V., Lange, Vinzenz, Stölzel, Friedrich, Röllig, Christoph, Middeke, Jan M., von Bonin, Malte, Thiede, Christian, Schäfer-Eckart, Kerstin, Müller-Tidow, Carsten, Krause, Stefan W., Kraus, Sabrina, Kaufmann, Martin, Hänel, Mathias, Serve, Hubert, Neubauer, Andreas, Bornhäuser, Martin, Schmidt, Alexander H., and Schetelig, Johannes

Published
2023
Full Text
View/download PDF

2. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Author

Middeke, Jan M., Metzeler, Klaus H., Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Desiree, Wörmann, Bernhard, Sockel, Katja, von Bonin, Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia D., Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Published
2022
Full Text
View/download PDF

3. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Published
2021
Full Text
View/download PDF

4. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

Author

Kriegsmann, Katharina, Manta, Calin, Schwab, Ricarda, Mai, Elias K., Raab, Marc S., Salwender, Hans J., Fenk, Roland, Besemer, Britta, Dürig, Jan, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Asemissen, Anne M., Heilmeier, Bernhard, Bertsch, Uta, Huhn, Stefanie, Müller-Tidow, Carsten, Goldschmidt, Hartmut, and Hundemer, Michael

Published
2023
Full Text
View/download PDF

5. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

Author

Merz, Maximilian, primary, Jauch, Anna, additional, Hielscher, Thomas, additional, Bochtler, Tilmann, additional, Schönland, Stefan Olaf, additional, Seckinger, Anja, additional, Hose, Dirk, additional, Bertsch, Uta, additional, Neben, Kai, additional, Raab, Marc Steffen, additional, Hillengass, Jens, additional, Salwender, Hans, additional, Blau, Igor Wolfgang, additional, Lindemann, Hans-Walter, additional, Schmidt-Wolf, Ingo G. H., additional, Scheid, Christof, additional, Haenel, Mathias, additional, Weisel, Katja C., additional, and Goldschmidt, Hartmut, additional

Published
2017
Full Text
View/download PDF

6. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

Author

Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Bochtler, Tilmann, Schönland, Stefan Olaf, Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc Steffen, Hillengass, Jens, Salwender, Hans, Blau, Igor Wolfgang, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo G. H., Scheid, Christof, Haenel, Mathias, Weisel, Katja C., and Goldschmidt, Hartmut

Abstract

We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)–65/German-Speaking MM Group (GMMG)–HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11;14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is of major prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results